Patent · US Active

Compounds for the treatment of hepatitis C

US8962651B2 · kind B2 · utility

1Cited by

8References

8Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Kyle J. Eastman · New Haven, US
Kyle E. Parcella · Wallingford, US
John F. Kadow · Wallingford, US

Key dates

Filing date	Mar 11, 2014
Grant date	Feb 24, 2015
Priority date	—
Expiry date	Mar 11, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D491/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.